Evusheld approved for COVID-19 in Japan
30 August 2022 13:00 BST Evusheld long-acting antibody combination approved for prevention and treatment of COVID-19 in Japan First global approval for Evusheld as a COVID-19 treatment PROVENT Phase III prevention trial showed reduced risk of developing symptomatic COVID-19 TACKLE Phase III treatment trial showed reduced risk of severe COVID-19 or death in high-risk patients AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in Japan for both prevention (pre-exposure prophylaxis) and treatment